Koiliari Erasmia I, Mouzas Ioannis, Alevizopoulos Georgios, Lesch Otto, Walter Henriette, Pasparakis Emmanouil L
Laboratory of Alcohology, Department of Pathology, Medical School of Crete, University of Crete, Herakleion, Greece.
Department of Psychiatry, General Hospital of Agios Nikolaos, Agios Nikolaos, Greece.
Front Psychiatry. 2025 Aug 8;16:1499400. doi: 10.3389/fpsyt.2025.1499400. eCollection 2025.
Aripiprazole, a partial D2 receptor agonist, is proposed to enhance prefrontal cortex (PFC) dopamine function, improving working memory and GABA transmission, which supports social functioning. Long-acting injectable (LAI) antipsychotics are known to improve patient adherence, leading to enhanced long-term effects on behavioral outcomes.
To evaluate whether aripiprazole LAI treatment improves general functioning, quality of life, and reduces hospitalizations in psychotic patients, both in community settings and within incarcerated populations.
The study included 55 patients, with 34 from the community and 21 incarcerated at a prison in Southeastern Greece (Neapolis). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) and the Clinical Global Impression-Severity (CGI-S) scale were used to assess outcomes. Comparisons were made between pre-treatment and post-treatment periods, with a minimum follow-up of six months.
• Demographics: Community patients (70.6% male) included 44.1% with paranoid schizophrenia. Incarcerated patients (all male) had an F29.0 diagnosis, with 57.1% exhibiting Cluster B personality disorder and all reporting psychoactive substance use.• Hospitalizations: Community patients' hospitalizations decreased from 1.4 to 0.1 over six months (p=0.001). Incarcerated patients' hospitalizations dropped from 0.6 to 0.0 (p=0.066), with no significant intergroup difference (p=0.150).• CGI-S: Community patients' scores improved from 6.0 to 3.9 (p<0.001). Incarcerated patients' scores improved from 5.3 to 3.2 (p<0.001), with no significant difference between groups (p=0.814).• Quality of Life: Community patients' scores rose from 0.5 to 3.0 (p<0.001), while incarcerated patients' scores also increased significantly (p<0.001).
This study of 34 community and 21 incarcerated patients revealed significant demographic and medical history differences. Both groups experienced reduced hospitalizations and improvements in CGI-S scores and quality of life following aripiprazole LAI administration. Community patients showed a greater reduction in hospitalizations, while clinical and quality-of-life improvements were comparable across groups.
阿立哌唑是一种部分D2受体激动剂，被认为可增强前额叶皮质（PFC）多巴胺功能，改善工作记忆和γ-氨基丁酸（GABA）传递，从而支持社交功能。长效注射（LAI）抗精神病药物已知可提高患者依从性，对行为结果产生更强的长期影响。
评估阿立哌唑长效注射剂治疗是否能改善精神病患者在社区环境和被监禁人群中的总体功能、生活质量并减少住院次数。
设计、背景和参与者：该研究纳入了55名患者，其中34名来自社区，21名被关押在希腊东南部的一所监狱（新波利斯）。使用世界卫生组织生活质量简表（WHOQOL-BREF）和临床总体印象-严重程度（CGI-S）量表评估结果。对治疗前和治疗后阶段进行比较，最短随访期为六个月。
• 人口统计学特征：社区患者（70.6%为男性）中，44.1%患有偏执型精神分裂症。被监禁患者（均为男性）诊断为F29.0，57.1%表现出B类人格障碍，且均报告使用过精神活性物质。
• 住院情况：社区患者的住院次数在六个月内从1.4次降至0.1次（p = 0.001）。被监禁患者的住院次数从0.6次降至0.0次（p = 0.066），组间差异无统计学意义（p = 0.150）。
• CGI-S评分：社区患者的评分从6.0提高到3.9（p < 0.001）。被监禁患者的评分从5.3提高到3.2（p < 0.001），组间差异无统计学意义（p = 0.814）。
• 生活质量：社区患者的评分从0.5提高到3.0（p < 0.001），被监禁患者的评分也显著提高（p < 0.001）。
这项对34名社区患者和21名被监禁患者的研究显示，两组在人口统计学特征和病史方面存在显著差异。两组在接受阿立哌唑长效注射剂治疗后，住院次数均减少，CGI-S评分和生活质量均有所改善。社区患者的住院次数减少幅度更大，而两组在临床和生活质量改善方面相当。
